Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Mizuho Analyst Says

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price objective upped by research analysts at Mizuho from $90.00 to $100.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the biopharmaceutical company's stock. Mizuho's price objective would suggest a potential upside of 11.31% from the company's current price.

A number of other analysts have also issued reports on GILD. Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Leerink Partners raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Wolfe Research started coverage on Gilead Sciences in a report on Friday, November 15th. They issued an "outperform" rating and a $110.00 price target for the company. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a report on Monday. Finally, Wells Fargo & Company lifted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Twelve equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $95.41.

Gilead Sciences Trading Up 1.4 %

Shares of GILD traded up $1.21 on Thursday, hitting $89.84. 2,542,532 shares of the stock traded hands, compared to its average volume of 7,092,298. The firm has a market capitalization of $111.96 billion, a P/E ratio of 997.33, a P/E/G ratio of 2.72 and a beta of 0.17. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $98.90. The stock's 50 day moving average is $87.15 and its two-hundred day moving average is $76.52.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.29 EPS. As a group, sell-side analysts predict that Gilead Sciences will post 4.38 earnings per share for the current year.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company's stock, valued at approximately $8,398,843.87. This represents a 1.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock valued at $4,968,674 in the last 90 days. Corporate insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently modified their holdings of GILD. MQS Management LLC purchased a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $250,000. Axxcess Wealth Management LLC increased its stake in Gilead Sciences by 24.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 17,916 shares of the biopharmaceutical company's stock valued at $1,312,000 after purchasing an additional 3,521 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in Gilead Sciences by 6.1% in the first quarter. Canada Pension Plan Investment Board now owns 1,410,443 shares of the biopharmaceutical company's stock valued at $103,315,000 after buying an additional 80,666 shares during the last quarter. Epoch Investment Partners Inc. raised its stake in shares of Gilead Sciences by 18.7% during the 1st quarter. Epoch Investment Partners Inc. now owns 887,978 shares of the biopharmaceutical company's stock valued at $65,044,000 after buying an additional 139,907 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in Gilead Sciences by 2.6% during the first quarter. Lazard Asset Management LLC now owns 969,733 shares of the biopharmaceutical company's stock valued at $71,032,000 after acquiring an additional 24,683 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.